MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,3A4B	SA00048111	46	F	SA00048111
Ordering Phys				**DOB** 06/10/1966
Client Order # SA00048111	**Account Information**			**Report Notes**
Collected 07/30/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 08/23/2012 14:04				

Test	Flag	Results	Unit	Reference Value	Perform Site*
CYP3A4 Genotype, B			REPORTED 07/31/2012 10:34		
CYP3A4 Genotype Result		CT detected			MCR
CYP3A4 Interpretation					MCR

This individual is heterozygous (CT) for the CYP3A4*22 (c.522-191C>T) allele. This genotype predicts lower CYP3A4 enzyme activity. Individuals with this genotype may require lower statin doses.
CYP3A4*22 genotype may also impact metabolism of other drugs that are CYP3A4 substrates, especially tacrolimus and cyclosporine. Absence of the *22 allele does not rule out the possibility that a patient harbors another variation that can impact the function of this enzyme, drug response, or drug side effects. The CYP3A4 genotype is only one factor that should be taken into consideration for statin dosing. Other factors include serum cholesterol concentrations and side effects such as myalgia and fatigue.

Direct polymorphism analysis of the CYP3A4 *22 (c.522-191C>T) allele is performed by a polymerase chain reaction (PCR)-based 5'-nuclease assay using fluorescently labeled detection probes. This DNA test will not detect all CYP3A4 genetic variants.
Laboratory developed test.

Reviewed by		Jamie Bruflat			MCR
Rapid DNA Extraction			REPORTED 07/31/2012 10:32		
Comment		See Below			MCR

Result: Genomic DNA was extracted.

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,3A4B	07/30/2012 13:00	Final
Page 1 of 1		** End of Report **

* Report times for Mayo performed tests are CST/CDT